No trial has ever tested oral GLP-1 compounds. So why are they the most expensive option?
Every efficacy figure you have seen for these drugs came out of a needle. Not one came out of a tablet.
Compounded ODT tirzepatide and semaglutide have never been tested in a clinical trial — and they cost more than the injection they are meant to replace.
The claim, and the evidence behind it
Orally disintegrating tablets are marketed as the needle-free path to the same results. Provider pages cite the familiar numbers — 20.9% in SURMOUNT-1, 14.9% in STEP 1 — alongside a product that dissolves under your tongue.
Those numbers were produced by a subcutaneous injection of an FDA-approved product. Every one of them. There is no ODT arm in SURMOUNT. There is no ODT arm in STEP. There is no published trial of a compounded ODT of either molecule at any dose.
| Trial | Arm | Result | Duration | Comparator | Source |
|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15 mg | −20.9% | 72 weeks | Placebo −3.1% | NEJM 2022 (Jastreboff et al.) |
| SURMOUNT-1 | Tirzepatide 10 mg | −19.5% | 72 weeks | NEJM 2022 | |
| SURMOUNT-1 | Tirzepatide 5 mg | −15.0% | 72 weeks | NEJM 2022 | |
| SURMOUNT-5 | Tirzepatide (max tolerated) | −20.2% | 72 weeks | vs semaglutide −13.7% | NEJM 2025 (Aronne et al.) |
| STEP 1 | Semaglutide 2.4 mg | −14.9% | 68 weeks | Placebo −2.4% | NEJM 2021 (Wilding et al.) |
| STEP 8 | Semaglutide 2.4 mg | −15.8% | 68 weeks | vs liraglutide 3.0 mg −6.4% | JAMA 2022 (Rubino et al.) |
| SCALE | Liraglutide 3.0 mg | −8.0% | 56 weeks | Placebo −2.6% | NEJM 2015 |
| SELECT | Semaglutide 2.4 mg | 20% MACE reduction | ~40 months | Cardiovascular outcomes | NEJM 2023 |
Every row is an injection. There is no ODT row because there is no ODT trial.
Why the dosage form is not a detail
Semaglutide and tirzepatide are peptides — large, fragile molecules. The gut is specifically designed to dismantle molecules like them, and the oral mucosa is not built to absorb them. This is not a theoretical concern; it is the central pharmacological problem of oral peptide delivery, and solving it is hard enough that Novo needed a specific absorption enhancer and a dedicated development programme to get an approved oral semaglutide to market at all.
Bioavailability, peak concentration, half-life, total exposure — all of these can differ enormously between an injection and a tablet. For a compounded ODT, none of them have been published. Nobody has shown you how much drug reaches your bloodstream, because nobody has measured it in public.
That does not prove ODT does not work. It means nobody has shown that it does.
And it costs more
Here is the part that should stop you. At NexLife — whose full pricing matrix we hold and publish — the ODT is the most expensive form of both molecules.
| Molecule | Microdose | Standard injection | ODT (oral) |
|---|---|---|---|
| Tirzepatide | $129 | $139 | $199 |
| Semaglutide | $110 | $119 | $165 |
You pay a premium of $46 to $60 a month — and you receive a product with no trial evidence behind its dosage form. That is an unusual thing to buy.
The one good reason to choose it
There is exactly one, and it is legitimate: you will not inject.
Needle phobia is real, and a treatment a patient will actually take can beat a better-evidenced treatment they will refuse. A clinician can reasonably support that trade. If you have tried to self-inject and cannot, an ODT is a defensible choice and you should not feel talked out of it.
What it is not is a cheaper option, a more effective option, or an equivalent option. If a provider implies any of those three, they are selling past the evidence.
What to ask
- What is the bioavailability of this specific formulation, and where is that published?
- Is there any pharmacokinetic data for this product at all?
- What dose am I getting, and how does it compare to the injectable dose it replaces?
- Why does it cost more than the injection if it has less evidence?
If the answer to question 1 or 2 cites SURMOUNT or STEP, the question has not been answered — those are injection trials. A provider who says plainly 'we don't have that data' is being more honest with you than one who reaches for the trial numbers.
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.
Frequently asked questions
Does ODT tirzepatide work?
No trial has tested it, so the honest answer is that nobody knows. All published efficacy data for tirzepatide comes from subcutaneous injection of an FDA-approved product.
Is ODT cheaper than the injection?
No. At NexLife it is the most expensive form of both molecules — $199 vs $139 for tirzepatide, $165 vs $119 for semaglutide, on the 12-month plan.
Who should use ODT?
Realistically, people who will not or cannot inject. That is a legitimate reason. Cost and efficacy are not.
Update history
| Date | What changed |
|---|---|
| September 4, 2026 | NexLife ODT pricing transcribed from published program pages. |
Sources
- U.S. Food and Drug Administration — labels, compounding guidance, adverse-event reporting.
- Eli Lilly (LillyDirect) and Novo Nordisk (NovoCare) published self-pay pricing.
- NexLife published program pages, transcribed July 11, 2026.
- Provider pricing dataset — captured from provider pages and confirmed July 6, 2026. Verified.
- Our pricing-verification methodology and source policy.
Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.
The numbers behind this page
What we do not claim in this guide
Every price quoted in this guide comes from the programme's own pricing page and carries the date it was captured.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
The figures in this guide sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
What the plan term is worth
The figures in this guide sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.
What is the cheapest verified GLP-1 programme?
NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.